TrialBMJ open2018

Is time to progression associated with post-progression survival in previously treated metastatic non-small cell lung cancer with BRAF V600E mutation? A secondary analysis of phase II clinical trial data.

Junlong Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.